Accuray Incorporated

DB:XEJ Stock Report

Market Cap: €175.6m

Accuray Valuation

Is XEJ undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of XEJ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate XEJ's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate XEJ's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for XEJ?

Key metric: As XEJ is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for XEJ. This is calculated by dividing XEJ's market cap by their current revenue.
What is XEJ's PS Ratio?
PS Ratio0.4x
SalesUS$444.20m
Market CapUS$184.03m

Price to Sales Ratio vs Peers

How does XEJ's PS Ratio compare to its peers?

The above table shows the PS ratio for XEJ vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average2x
PUS PULSION Medical Systems
3.8xn/a€134.4m
SBS Stratec
1.3x7.7%€336.7m
DRW3 Drägerwerk KGaA
0.2x4.2%€789.3m
EUZ Eckert & Ziegler
2.8x6.3%€770.9m
XEJ Accuray
0.4x5.5%€184.0m

Price-To-Sales vs Peers: XEJ is good value based on its Price-To-Sales Ratio (0.4x) compared to the peer average (2x).

Price to Sales Ratio vs Industry

How does XEJ's PS Ratio compare vs other companies in the DE Medical Equipment Industry?

4 CompaniesPrice / SalesEstimated GrowthMarket Cap
DRW3 Drägerwerk KGaA
0.2x4.2%US$827.31m
PHH2 Paul Hartmann
0.3xn/aUS$789.28m
U4W0 Quotient
0.07xn/aUS$2.78m
MF6 MagForce
0.3xn/aUS$404.27k
No more companies available in this PS range
XEJ 0.4xIndustry Avg. 3.7xNo. of Companies4PS01.63.24.86.48+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: XEJ is good value based on its Price-To-Sales Ratio (0.4x) compared to the European Medical Equipment industry average (3.5x).

Price to Sales Ratio vs Fair Ratio

What is XEJ's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

XEJ PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.4x
Fair PS Ratio0.5x

Price-To-Sales vs Fair Ratio: XEJ is good value based on its Price-To-Sales Ratio (0.4x) compared to the estimated Fair Price-To-Sales Ratio (0.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst XEJ forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€1.71
€5.78
+238.1%
8.9%€6.61€5.19n/a4
Nov ’25€1.57
€5.58
+255.5%
8.9%€6.38€5.01n/a4
Oct ’25€1.59
€5.58
+251.0%
8.9%€6.38€5.01n/a4
Sep ’25€1.94
€5.58
+187.7%
8.9%€6.38€5.01n/a4
Aug ’25€1.68
€5.50
+227.6%
11.8%€6.42€4.59n/a4
Jul ’25€1.67
€5.55
+232.5%
11.8%€6.48€4.63n/a4
Jun ’25€1.46
€5.57
+281.7%
11.8%€6.50€4.64n/a4
May ’25€2.06
€8.17
+296.6%
30.6%€12.14€5.60n/a4
Apr ’25€2.20
€8.17
+271.4%
30.6%€12.14€5.60n/a4
Mar ’25€2.36
€8.17
+246.2%
30.6%€12.14€5.60n/a4
Feb ’25€2.36
€7.97
+237.9%
35.7%€11.96€5.52n/a3
Jan ’25€2.58
€7.79
+202.0%
31.7%€11.92€5.50n/a4
Dec ’24€2.36
€7.79
+230.2%
31.7%€11.92€5.50n/a4
Nov ’24€2.46
€7.86
+219.4%
29.4%€12.31€5.68€1.575
Oct ’24€2.54
€7.56
+197.6%
29.4%€11.84€5.46€1.595
Sep ’24€2.58
€7.56
+193.0%
29.4%€11.84€5.46€1.945
Aug ’24€3.82
€7.38
+93.2%
29.4%€11.56€5.34€1.685
Jul ’24€3.54
€7.53
+112.8%
29.4%€11.80€5.45€1.675
Jun ’24€3.40
€7.53
+121.5%
29.4%€11.80€5.45€1.465
May ’24€2.82
€7.53
+167.1%
29.4%€11.80€5.45€2.065
Apr ’24€2.64
€7.48
+183.5%
27.5%€11.91€5.50€2.206
Mar ’24€2.69
€7.48
+177.8%
27.5%€11.91€5.50€2.366
Feb ’24€2.29
€8.37
+266.4%
27.5%€13.33€6.15€2.366
Jan ’24€1.91
€8.37
+339.3%
27.5%€13.33€6.15€2.586
Dec ’23€1.95
€8.37
+330.3%
27.5%€13.33€6.15€2.366
Nov ’23€2.04
€8.08
+297.1%
25.4%€12.60€6.79€2.466

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Shandong Weigao Group Medical Polymer

HK$20.7b

Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.

UK2

HK$0.54

7D

-1.8%

1Y

-37.1%

Fagron

€1.3b

A pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide.

4A5

€18.18

7D

-2.7%

1Y

6.1%

LNA Santé

€242.3m

Engages in the management and operation of health establishments.

2N3

€23.25

7D

-6.8%

1Y

15.7%